Topological robustness analysis of protein interaction networks reveals key targets for overcoming chemotherapy resistance in glioma

Imagem de Miniatura
Arquivos
art_AZEVEDO_Topological_robustness_analysis_of_protein_interaction_networks_reveals_2015.PDF (1.11 MB)
Citações na Scopus
38
Tipo de produção
article
Data de publicação
2015
Editora
NATURE PUBLISHING GROUP
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
SCIENTIFIC REPORTS, v.5, article ID 16830, 13p, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Biological networks display high robustness against random failures but are vulnerable to targeted attacks on central nodes. Thus, network topology analysis represents a powerful tool for investigating network susceptibility against targeted node removal. Here, we built protein interaction networks associated with chemoresistance to temozolomide, an alkylating agent used in glioma therapy, and analyzed their modular structure and robustness against intentional attack. These networks showed functional modules related to DNA repair, immunity, apoptosis, cell stress, proliferation and migration. Subsequently, network vulnerability was assessed by means of centrality-based attacks based on the removal of node fractions in descending orders of degree, betweenness, or the product of degree and betweenness. This analysis revealed that removing nodes with high degree and high betweenness was more effective in altering networks' robustness parameters, suggesting that their corresponding proteins may be particularly relevant to target temozolomide resistance. In silico data was used for validation and confirmed that central nodes are more relevant for altering proliferation rates in temozolomide-resistant glioma cell lines and for predicting survival in glioma patients. Altogether, these results demonstrate how the analysis of network vulnerability to topological attack facilitates target prioritization for overcoming cancer chemoresistance.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/12753
Referências
  1. Jia J, 2009, NAT REV DRUG DISCOV, V8, P111, DOI 10.1038/nrd2683
  2. Kumar DM, 2013, PROTEOMICS, V13, P2113, DOI 10.1002/pmic.201200261
  3. Scardoni G, 2009, BIOINFORMATICS, V25, P2857, DOI 10.1093/bioinformatics/btp517
  4. Laubenbacher R, 2009, BBA-REV CANCER, V1796, P129, DOI 10.1016/j.bbcan.2009.06.001
  5. Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
  6. Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509
  7. Borges KS, 2012, J CANCER RES CLIN, V138, P405, DOI 10.1007/s00432-011-1111-0
  8. Huang G, 2014, ANTI-CANCER AGENT ME, V14, P9, DOI 10.2174/18715206113139990141
  9. Chaussabel D, 2008, IMMUNITY, V29, P150, DOI 10.1016/j.immuni.2008.05.012
  10. Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138
  11. Johannessen TCA, 2012, EXPERT REV ANTICANC, V12, P635, DOI [10.1586/era.12.37, 10.1586/ERA.12.37]
  12. Yoshino A, 2010, INT J ONCOL, V36, P1367, DOI 10.3892/ijo_00000621
  13. Happold C, 2012, J NEUROCHEM, V122, P444, DOI 10.1111/j.1471-4159.2012.07781.x
  14. Tang J, 2014, CURR PHARM DESIGN, V20, P23
  15. Tian T, 2015, BIOCHEM BIOPH RES CO, V463, P638, DOI 10.1016/j.bbrc.2015.05.115
  16. Breitkreutz D, 2012, P NATL ACAD SCI USA, V109, P9209, DOI 10.1073/pnas.1201416109
  17. Demuth T, 2007, MOL CANCER THER, V6, P1212, DOI 10.1158/1535-7163.MCT-06-0711
  18. Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019
  19. McCubrey JA, 2012, ONCOTARGET, V3, P1068
  20. Gursoy A, 2008, BIOCHEM SOC T, V36, P1398, DOI 10.1042/BST0361398
  21. Assenov Y, 2008, BIOINFORMATICS, V24, P282, DOI 10.1093/bioinformatics/btm554
  22. Montojo J, 2010, BIOINFORMATICS, V26, P2927, DOI 10.1093/bioinformatics/btq562
  23. Ramaswamy S, 2007, NEW ENGL J MED, V357, P299, DOI 10.1056/NEJMcibr072593
  24. He WL, 2015, ANTI-CANCER DRUG, V26, P293, DOI 10.1097/CAD.0000000000000197
  25. Azmi AS, 2014, FUTURE MED CHEM, V6, P529, DOI 10.4155/fmc.14.6
  26. Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108
  27. Gimenez M, 2012, PROTEOMICS, V12, P2632, DOI 10.1002/pmic.201200034
  28. Sun G, 2013, CANCER BIOTHER RADIO, V28, P327, DOI 10.1089/cbr.2012.1380
  29. Chakravarti A, 2004, J CLIN ONCOL, V22, P1926, DOI 10.1200/JCO.2004.07.193
  30. Bruyere C, 2011, INT J ONCOL, V38, P1453, DOI 10.3892/ijo.2011.964
  31. Takemoto K, 2013, BIOSYSTEMS, V113, P149, DOI 10.1016/j.biosystems.2013.06.003
  32. Kohsaka S, 2012, MOL CANCER THER, V11, P1289, DOI 10.1158/1535-7163.MCT-11-0801
  33. Wang E, 2015, SEMIN CANCER BIOL, V30, P4, DOI 10.1016/j.semcancer.2014.04.002
  34. Chan SY, 2012, CIRC RES, V111, P359, DOI 10.1161/CIRCRESAHA.111.258541
  35. Yeung YT, 2013, BRIT J PHARMACOL, V168, P591, DOI 10.1111/bph.12008
  36. Auger N, 2006, MOL CANCER THER, V5, P2182, DOI 10.1158/1535-7163.MCT-05-0428
  37. Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
  38. Chen WH, 2014, J NEURO-ONCOL, V120, P43, DOI 10.1007/s11060-014-1535-x
  39. Cherry EM, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0273-1
  40. Cui Bo, 2010, J Biomed Res, V24, P424, DOI 10.1016/S1674-8301(10)60057-7
  41. Cui QH, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100200
  42. Dezso Z, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-36
  43. Epple LM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073267
  44. Fukushima S, 2014, BRAIN TUMOR PATHOL, V31, P11, DOI 10.1007/s10014-013-0139-z
  45. Gao QL, 2013, EXPERT OPIN INV DRUG, V22, P1023, DOI 10.1517/13543784.2013.806484
  46. Han ZX, 2014, BRAIN TUMOR PATHOL, V31, P234, DOI 10.1007/s10014-013-0161-1
  47. Holme P, 2002, PHYS REV E, V65, DOI [10.1103/PhysRevE.65.026107, 10.1103/PhysRevE.65.056109]
  48. Iyer S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059613
  49. Jiang Y., 2014, COMM SEC C, V2014, P1
  50. Kar G, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000601
  51. Khosravi Pegah, 2014, Iran J Cancer Prev, V7, P204
  52. Lin LL, 2014, DRUG DISCOV TODAY, V19, P1402, DOI 10.1016/j.drudis.2014.04.016
  53. Liu R, 2012, SCI REP-UK, V2, DOI 10.1038/srep00813
  54. Mizuno H., 2009, BMC MED GENOMICS, V24, P2
  55. Morris JH, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-436
  56. Nath A., 2012, SYSTEMS BIOL CANC RE, V2012, P339
  57. Omuro A., 2013, JAMA-J AM MED ASSOC, V10, P1842
  58. Wang JH, 2014, BIOINFORMATICS, V30, P2534, DOI 10.1093/bioinformatics/btu241
  59. Xionglei H., 2006, PLOS GENET, V2, pe88
  60. Ye F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080397
  61. Yinghu H., 2010, LECT NOTES COMPUTER, V6216, P418
  62. Zanotto-Filho A, 2015, CANCER LETT, V358, P220, DOI 10.1016/j.canlet.2014.12.044
  63. Zhang JH, 2010, ONCOLOGY-BASEL, V78, P103, DOI 10.1159/000306139
  64. Zhang R, 2015, J NEURO-ONCOL, V121, P63, DOI 10.1007/s11060-014-1607-y

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPE
Artigos e Materiais de Revistas Científicas - LIM/36
Artigos e Materiais de Revistas Científicas - ODS/03